Traws Pharma Inc. saw its stock price climb sharply on Friday after the clinical-stage biopharmaceutical company announced plans to accelerate the development of antiviral candidates targeting hantavirus. The move comes in the wake of a deadly outbreak on a cruise ship that has drawn global attention to the rare but often fatal disease.
Outbreak Details and Market Reaction
The World Health Organization confirmed five cases of hantavirus among passengers and crew on the MV Hondius, a cruise vessel that has been stranded off the coast of Cape Verde. Three of those infected have died. The WHO noted that while the Andes strain of hantavirus can be transmitted between humans, such spread is rare and typically requires prolonged close contact. The public health risk remains low, the agency added.
Shares of Traws Pharma jumped 21.8% to $2.07 on Friday, after reaching an intraday high of $2.55. The rally lifted the company's market capitalization to approximately $18.3 million. The stock move was driven by the company's announcement that it would prioritize hantavirus drug development, though it has not yet named a lead candidate.
Company Background and Pipeline
Headquartered in Newtown, Pennsylvania, Traws Pharma describes itself as a clinical-stage biopharmaceutical company focused on respiratory viral illnesses. Its pipeline includes two oral antiviral candidates: ratutrelvir, aimed at COVID-19 and long COVID, and tivoxavir marboxil, targeting seasonal influenza and H5N1 bird flu. However, the tivoxavir program remains under a clinical hold imposed by the U.S. Food and Drug Administration due to toxicology concerns, as disclosed by the company in April.
The company has no approved products on the market, which underscores the speculative nature of Friday's rally. Chief Scientific Officer C. David Pauza stated that the company "plans to rapidly advance clinical candidates" for hantavirus, while Chief Medical Officer Robert R. Redfield described the initiative as an emergency push for "life-saving treatments."
Hantavirus: A Deadly but Rare Threat
Hantavirus is typically transmitted to humans through contact with urine, droppings, or saliva from infected rodents. According to the WHO, fatality rates in the Americas can reach 50%. There is currently no approved targeted treatment or vaccine for hantavirus; care is limited to supportive measures, often requiring intensive care. The outbreak on the MV Hondius has highlighted the urgent need for effective therapies, as severe cases can rapidly progress to pneumonia, acute respiratory distress syndrome, and shock.
Financial Position and Challenges Ahead
Capital remains a key concern for the company. In April, Traws secured approximately $10 million through a private investment in public equity (PIPE) and has the potential to access up to $50 million more if certain warrant milestones are met. Chief Executive Iain Dukes said the funding "positions us to advance our influenza program" and to conduct a human challenge trial in the United Kingdom.
Despite the positive market reaction, significant hurdles remain. The company has yet to select a specific hantavirus drug candidate, demonstrate its efficacy in clinical trials, and obtain regulatory approval. Analysts caution that Friday's stock move is primarily based on disease urgency rather than concrete evidence of a viable hantavirus product.
Industry Context
The oral antiviral market is dominated by larger players. Pfizer's Paxlovid is approved in the U.S. for high-risk adults with mild-to-moderate COVID-19, while Roche and Shionogi's Xofluza is cleared for influenza treatment and post-exposure prevention. Traws Pharma remains a small player, working to translate its antiviral library into a hantavirus program amid a competitive landscape.
The cruise ship incident continues to unfold. Reuters reported that the MV Hondius lingered off Cape Verde for four days, during which specialist teams evacuated three individuals. The vessel is now heading to Tenerife with approximately 150 passengers and crew, all of whom will disembark under medical supervision.
